Thymosin Alpha-1
Also known as: Ta1, Zadaxin
Thymic peptide: immune system modulator, enhances T-cell function.
- Typical dose
- 1.5 mg – 1.6 mg
- Frequency
- twice weekly
- Route
- Subcutaneous
- Half-life
- 2 hours
- Routes
- Subcutaneous
- Status
- Approved in 30+ countries; orphan drug designation (not approval) in US
Benefits
- Immune system enhancement
- Anti-viral
- Anti-tumor immune activity
- Vaccine adjuvant
Dosing
A common research range for Thymosin Alpha-1 is 1.5 mg to 1.6 mg twice weekly. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Reconstitution
A typical reconstitution for Thymosin Alpha-1 is 5 mg of peptide in 1 mL of bacteriostatic water, giving roughly 5 mg per mL. Vial's built-in calculator works out the exact syringe draw for any vial size and dose.
Half-life
Thymosin Alpha-1 has an approximate half-life of 2 hours. Vial plots the real concentration curve from your logged doses so you can see peak windows and when levels taper.
Storage
2-8°C post-reconstitution.
Reported side effects
- Injection site reactions
Contraindications
- Immunosuppressive therapy (relative)
Commonly stacked with
Track Thymosin Alpha-1 with Vial
Vial logs every Thymosin Alpha-1 dose, plots its half-life curve, calculates reconstitution math, and keeps your whole protocol on schedule — on-device and private. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Thymosin Alpha-1 is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.